Blog on HPV Vaccine, page-37

Well said Buyholdsell.
Fox doing some posts today..sorry..bored..surfs shit. Anyway..
The riskiness of AHZ is still in our blue sky vax investments. That will be sorted this year.
The long term choice to invest is into a company with gold standard product results. No calcification after 7 years and the worlds top surgeons embracing it, experimenting and expanding its applications. Disruptive technology too, in that the ADAPT tissue is unique in its properties, well patented , and is slowly but surely taking market share from its competitors in very fussy markets where surgeons hold peoples lives in their hands when takng the step to embarking on a change to using it over existing products.
These are huge markets. Progress is slow but sure in building centres, reputation ,trust, repeat orders and consequent revenue.
Time will tell but it is still early days in launching the cardiocel revolution in the market place.
There is a long history ahead for cardiocel and related products whch will surely eventually see an SP that well refects it in the huge cardiovascular device market.
Blah blah. Hic.
Fox